compounding pharmacy and semaglutide Troubling Findings in Study of GLP-1 Compounders Sublingual Semaglutide: A Convenient Weight

Key findings of the study are as follows: 76 of 145 410 patients (incidence rate 1.33 events per 10 000 person years) treated with GLP1 receptor agonists and 184 of 291 667 patients (incidence rate 1.46 events per 10 000 person years) treated with DPP4 inhibitors developed thyroid cancer

If youre currently taking oral oestrogen, your healthcare provider might recommend switching to a patch-based (transdermal) formulation while youre on GLP-1 treatment

It is refreshing, easy to sip on the go, and surprisingly filling

You should not buy it without a doctors approval first

Whilst mild hair thinning during GLP-1 treatment may not require immediate intervention, certain circumstances warrant medical evaluation

What changed on July 23, 2026 : alongside two new Phase 3 readouts, Lilly said it plans to submit a Biologics License Application (BLA) for retatrutide to the FDA in the first quarter of 2027